Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
02 juil. 2020 07h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss...
MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research
11 juin 2018 08h00 HE
|
Traders News Source LLC
NEW YORK, NY, June 11, 2018 (GLOBE NEWSWIRE) -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a...